Table 2.
Fitted values of parameters for the latency functions of Kocher et al. [4] and Ulanowski et al. [7] as given by Eqs. (1) and (2), estimated by least squares from stochastic model, with given rates of malignant cell division by endpoint (values from Table 1).
| Endpoint | Subtypes | Implied malignant cell division rate (G) (/cell/year) | Latency function of Kocher et al. [4] (see Eq.(1)) | Latency function of Ulanowski et al. [7] (see Eq.(2)) | Reference | ||
|---|---|---|---|---|---|---|---|
| μ | S | μ | η | ||||
| Leukaemia | Childhood ALL | 63.292 | 0.376 | 0.016 | 0.375 | 23.806 | Frei and Freireich [61] |
| Adult AML | 14.892 | 1.499 | 0.067 | 1.497 | 22.361 | Gregory et al. [62] | |
| Lung cancer | Squamous cell carcinoma and other non-adenocarcinoma | 3.247a | 6.407 | 0.308 | 6.398 | 20.840 | Geddes [63] and Obayashi et al. [64] |
| Adenocarcinoma | 1.271a | 15.628 | 0.787 | 15.602 | 19.904 | ||
| Breast cancer | 1.987b | 10.223 | 0.503 | 10.208 | 20.350 | Ryu et al. [65], Spratt et al. [66], Kusama et al. [67] and Weedon-Fekjær et al. [68] | |
| Colorectal | 3.427c | 6.086 | 0.292 | 6.077 | 20.894 | Bolin et al. [45], Burke et al. [46] and Knudsen et al. [47] | |
| Prostate | 0.576d | 21.110 | 1.735 | 21.020 | 12.209 | Egawa et al. [17], D’Amico and Hanks [42] and Schmid et al. [18] | |
| Hepatocellular carcinoma | 1.808 | 11.182 | 0.553 | 11.164 | 22.256 | Nathani et al. [69] | |
| Thyroid | 0.629e | 19.485 | 1.590 | 19.403 | 12.317 | Oh et al. [38], Miyauchi et al. [39] and Kihara et al. [40] | |
| Head and neck | 4.150 | 5.072 | 0.241 | 5.064 | 21.085 | Jensen et al. [70] | |
| Oropharyngeal | 2.637 | 7.810 | 0.379 | 7.798 | 22.931 | Waaijer et al. [71] | |
In all cases except prostate and thyroid we assume the limiting malignancy number of Nlim = 109 with the implied rate of detection of cancer/malignant cell/year of 2.9957 × 10−9, but for prostate and thyroid we assume the limiting malignancy number of Nlim = 106 with the implied rate of detection of cancer/malignant cell/year of 2.9957 × 10–6.
ALL acute lymphoblastic leukaemia, AML acute myeloid leukaemia.
aMean of values of G derived from studies of Geddes [63] and Obayashi et al. [64].
bMean of values of G derived from studies of Ryu et al. [65], Spratt et al. [66], Kusama et al. [67] and Weedon-Fekjær et al. [68].
cMean of values of G derived from studies of Bolin et al. [45], Burke et al. [46] and Knudsen et al. [47].
dMean of values of G derived from study of Egawa et al. [17] and D’Amico and Hanks [42] and separate estimates for clinically-confined and non-organ confined cases from study of Schmid et al. [18].
eMean of values of G derived from studies of Oh et al. [38], Miyauchi et al. [39] and Kihara et al. [40].